Treatment of intrahepatic recurrence after hepatectomy for hepatocellular carcinoma

8Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Prognostic factors after treatment for intrahepatic recurrent hepatocellular carcinoma (RHCC) after hepatic resection (Hx) are controversial. The current study aimed to examine the impact of treatment modality on the prognosis of intrahepatic RHCC following Hx. Methods: For control of variables, the subjects were 56 patients who underwent treatment for intrahepatic RHCC, three or fewer tumors, each measuring ≤3 cm in diameter without macroscopic vascular invasion (MVI), between 2000 and 2011. Retreatment consisted of repeat Hx (n = 23), local ablation therapy (n = 11) and transarterial chemoembolization or transcatheter arterial infusion (TACE/TAI) (n = 22). We retrospectively investigated the relation between type of treatment for RHCC and overall survival (OS) as well as disease-free survival (DFS). Results: In multivariate (MV) analysis, the poor prognostic factors in DFS after retreatment consisted of disease-free interval (DFI) (≤1.5 y) (P =.011), type of retreatment (TACE/TAI) (P =.002), age (<65 y old) (P =.0022), perioperative RBC transfusion (P =.025), while those in OS after retreatment were DFI (≤1.5 y) (P

Cite

CITATION STYLE

APA

Matsumoto, M., Yanaga, K., Shiba, H., Wakiyama, S., Sakamoto, T., Futagawa, Y., … Ikegami, T. (2021). Treatment of intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. Annals of Gastroenterological Surgery, 5(4), 538–552. https://doi.org/10.1002/ags3.12449

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free